Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
R V FlemingM T Philipp

Abstract

It was recently reported that antibody to C(6), a peptide that reproduces an invariable region of the VlsE lipoprotein of Borrelia burgdorferi, declined in titer by a factor of four or more in a significant proportion of patients after successful antibiotic treatment of acute localized or disseminated Lyme borreliosis. The present study evaluated the C(6) test as a predictor of therapy outcome in a population of patients with post-treatment Lyme disease syndrome. The serum specimens tested were from patients with well-documented, previously treated Lyme borreliosis who had persistent musculoskeletal or neurocognitive symptoms. All of the patients had participated in a recent double-blind, placebo-controlled antibiotic trial in which serum samples were collected at baseline and 6 months thereafter, i.show $132#e. 3 months following treatment termination. In this patient population no correlation was found between a decline of C(6) antibody titer of any magnitude and treatment or clinical outcome. Antibodies to C(6) persisted in these patients with post-treatment Lyme disease syndrome following treatment, albeit at a markedly lower prevalence and titer than in untreated patients with acute disseminated Lyme disease. The results i...Continue Reading

Citations

Oct 27, 2009·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Bjørn-Erik KristiansenAndreas Emmert
Apr 16, 2014·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Reidar HjetlandElling Ulvestad
May 8, 2008·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Amy L JohnsonYung-Fu Chang
Apr 16, 2010·Clinical and Vaccine Immunology : CVI·Peter D BurbeloAdriana Marques
Nov 20, 2012·Acta Veterinaria Hungarica·Thomas J DiversBettina Wagner
Jan 1, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elzbieta JacekArmin Alaedini
Mar 13, 2020·Frontiers in Medicine·Alison W Rebman, John N Aucott

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.